Antibody-drug conjugates (ADCs) are a type of cancer therapy designed to deliver a cancer-killing drug directly to tumors. This targeted approach can reduce damage to healthy cells, avoiding some of the side effects patients often experience with traditional treatments.

Pfizer scientists are working to unlock the full potential of ADCs to improve outcomes for patients across many different cancer types and change the future of cancer care.

свернуть